Trial Information

Storing Blood for Analysis of DNA and Protein of Patients With Glioma in MAASTRO Clinic

It has already been known for a long time that cancer is a genetic disorder and that the
development of the illness is a very complex interaction between genetic and surrounding
factors. Also the response on therapy and the development and seriousness of side effects is
stipulated by this complicated collaboration of genetic and surrounding factors. Moreover it
is not only the DNA that plays an important role but also the systems of control at the
protein level. At this moment a lot of questions remain to be answered because up till now
the studies were of rather restricted statistical strength with frequently inconsistent
dates and moreover retrospective. Major retrospective studies are necessary to distinguish
the relationship between DNA/protein patterns and clinically relevant endpoints like
prognosis and toxicity in which an as broad as possible patient group is being monitored.
For this reason we want to draw blood in the MAASTRO clinic of all patients with glioma and
store it encrypted so that we can perform DNA and protein analyses in the future and to
correlate the results with survival and toxicity of the treatment.